美罗培南治疗老年卒中相关性肺炎的临床疗效及安全性分析

The Clinical Efficacy and Safety Analysis of Meropenem in the Treatment of Associated Pneumonia in Senile Stroke

目的探讨美罗培南治疗老年卒中相关性肺炎(SAP)的临床疗效及安全性分析。方法选取2016年3月—2017年4月我院收治的70例老年卒中相关肺炎患者,在常规治疗基础上对所有患者实施美罗培南治疗,观察期疗效及症状消失时间。结果本组70例患者经治疗后,痊愈37例,有效25例,无效8例,治疗总有效率88.57%。治疗期间发生不良反应5例(占7.14%),死亡2例,死亡率2.86%。结论临床中对老年卒中相关性肺炎患者在常规治疗基础上给予美罗培南治疗,具有临床疗效,患者炎症得到良好控制,安全性较高。

Objective To explore the clinical efficacy and safety of meropenem in treating senile stroke associated pneumonia （SAP）. Methods From March 2016 to April 2017, 70 cases of senile stroke associated pneumonia patients in our hospital were treated with meropenem on the basis of routine therapy. The curative effect and duration of symptoms were observed. Results After treatment of 70 cases, 37 cases were cured, 25 cases were effective, 8 cases were ineffective, the total effective rate was 88.57%. 5 cases （7.14%） with adverse reaction in treatment period, 2 cases （2.86%） with deadly. Conclusion Meropenem treatment on the basis of routine treatment for pneumonia in elderly stroke patients has significant clinical efficacy, inflammation in patients can achieve good control and high safety.